Share this article on:

Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report

Burzynski, Stanislaw R. MD, PhD; Janicki, Tomasz J. MD; Burzynski, Gregory S. MD; Marszalek, Ania MD

Journal of Pediatric Hematology/Oncology: October 2014 - Volume 36 - Issue 7 - p e433–e439
doi: 10.1097/MPH.0000000000000020
Online Articles: Clinical and Laboratory Observations

Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for 4 years. Subsequently, his brain tumor transformed into a GS. Prior treatment of his LGA included subtotal tumor resection 3 times, standard radiation therapy, and Gamma Knife procedure twice. His LGA was also treated with a standard chemotherapy regimen of carboplatin and vincristine, and his GS with subtotal resection, high-dose cyclophosphamide, and thiotepa with stem cell rescue and temozolomide. Unfortunately, he developed disseminated disease with multiple lesions and leptomeningeal involvement including a tumor occupying 80% of the pons. Upon presentation at our clinic, he had rapidly progressing disease. He received treatment with antineoplastons (ANP) A10 and AS2-1 for 6 years and 10 months under special exception to our phase II protocol BT-22. During his treatment with ANP his tumor stabilized, then decreased, and, ultimately, did not show any metabolic activity. The patient’s response was evaluated by magnetic resonance imaging and positron emission tomography scans. His pathology diagnosis was confirmed by external neuropathologists, and his response to the treatment was determined by central radiology review. He experienced the following treatment-related, reversible toxicities with ANP: fatigue, xerostomia and urinary frequency (grade 1), diarrhea, incontinence and urine color change (grade 2), and grade 4 hypernatremia. His condition continued to improve after treatment with ANP and, currently, he complains only of residual neurological deficit from his previous surgery. He achieved a complete response, and his overall and progression-free survival is in excess of 13 years. This report indicates that it is possible to obtain long-term survival of a child with a highly aggressive recurrent GS with diffuse pontine involvement with a currently available investigational treatment.

Burzynski Clinic, Houston, TX

The clinical trial was sponsored by the Burzynski Research Institute Inc.

S.R.B. is chairman of the Board of Directors and President of BRI Inc. G.S.B. is a member of the Board of Directors of BRI Inc.T.J.J. is the Vice President of Clinical Trials at BRI Inc. All authors are employed by Burzynski Clinic.

Reprints: Gregory S. Burzynski, MD, Burzynski Clinic, 9432 Katy Freeway, Houston, TX 77055 (e-mail:

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received February 27, 2013

Accepted August 20, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.